Beyond Longevity

In this ViVE conference bonus episode of Beyond Longevity, recorded live at the ViVE event in Los Angeles, the conversation explores how BioAro is seeking to bring different strands of personalised health data together within a single longevity platform.Brock Hay explains BioAro’s approach to integrating genomics, microbiome testing, biomarker analysis, AI-driven interpretation, and personalized supplementation. The central idea is that health and longevity cannot be understood through any single test alone, but require a broader and more connected picture of the individual.The conversation also examines one of the most important questions in modern health technology, namely data privacy. As more companies collect deeply personal biological information, the focus turns to who owns that data, how it is stored, and whether individuals truly remain in control of how it is used.The episode also explores how tools such as telomere testing, methylation analysis, gut microbiome testing, and athlete-focused genomics are being positioned within the wider move towards preventive health. It also considers how far today’s longevity interventions can genuinely take us, and where the limits of current science and commercial promise still remain.Links:https://bioaro.com/linkedin.com/in/brock-hay-9520447100:00 Welcome to Beyond Longevity02:11 Meet Bio Arrow at ViVE02:23 All in One Longevity Platform05:02 Genomics Explained Simply07:03 Privacy and Data Security09:13 Genes as Prevention Tools11:23 Methylation and Telomeres12:08 Who It’s For and Pricing16:13 Key Longevity Biomarker17:40 Telomeres and Supplements22:13 Future of Personalized Medicine24:10 Gut Microbiome Testing28:43 Founder Story and Integration32:38 Research vs Consent37:06 Vatra Decentralized Storage38:58 Rapid Fire Longevity Tips41:06 Closing Takeaways

On Beyond Longevity, Corinne Briaud Manon discusses women’s healthspan through the lenses of science, consumer trust and commercial execution, drawing on her experience in major corporates and her work across Green Marlin, which advises health and longevity startups, and LongHER, a women’s healthspan community platform.She explains how the two initiatives connect, including how startups can test their propositions with real consumers, and outlines common early-stage pitfalls such as focusing too much on technical detail and not enough on real consumer need, lacking competitive awareness and structure, and letting passion override business discipline.The conversation explores what “science-backed” should really mean, why longevity is currently a kind of wild west with real credibility risks, and why women’s health needs to become a serious business if it is to address historic underinvestment.Corinne emphasises the importance of getting the basics right first for women, including basic health assessments, body composition, sleep, movement, strength and social connection, rather than spending blindly on superficial solutions. She also points out that access remains skewed towards the privileged and that prevention will need to be properly incentivised if it is to reach the masses.Instagram: @‌longher_collectivehttps://www.linkedin.com/in/corinne-briaud-manon/00:00 Welcome and Guest Intro01:38 Two Ventures Overview02:43 Ecosystem Linking Both04:17 How Longher Helps Startups06:20 Green Marlin Origin Story07:39 Startup Gaps and Fixes11:48 Passion Versus Business13:00 Spotting Real Innovation14:44 Authenticity in Longevity Clinics16:53 From Lab to Market18:53 What Science Backed Means20:56 Longevity Wild West24:09 Why Womens Health Must Scale28:01 Workplace Healthspan Shift28:30 Workplace Health Costs29:19 Menopause Support Programs30:57 Women Led Health Startups32:09 Beauty Versus Longevity Hype33:54 Muscle Health Foundations35:29 Where To Begin Basics39:17 Stop Wasting On Superficial41:14 Longevity Access Inequality45:19 Prevention Model Shift50:02 Future Of Longevity Trust51:49 Rapid Fire Takeaways55:32 Closing Reflections

Professor Lorna Harries has spent more than two decades studying why cells age and what might be done about it. In this episode, she explains one of the most overlooked mechanisms in ageing biology, RNA splicing. When cells lose control of this process, they become stressed, dysfunctional and can tip into senescence, a state that contributes to ageing across almost every organ system.She explains what senescent cells actually do, how the signals they release can spread damage from one tissue to another, and why calling them “zombie cells” does not come close to telling the full story. We talk about the possibility of intervening before cells reach an irreversible state, why targeting the biology of ageing itself may matter more than tackling diseases one at a time, and what meaningful rejuvenation should really look like.Prof Lorna also discusses the challenge of turning lab science into therapies through her spin-out SENISCA, her work with L’Oréal, and why conditions such as IPF are an important place to begin. Along the way, she addresses the tougher questions too, including how longevity science moves from promise to treatment, where the field risks drifting into hype, and whether these advances will be available to the many or only the few.Links:http://www.senisca/http://www.iscarna.com/https://teamrna.wixsite.com/harrieslabhttps://experts.exeter.ac.uk/1873-lorna-harriesInnovate UK ICURe Programmehttps://iuk-business-connect.org.uk/programme/icure/ 00:00 Podcast Intro Guest Setup01:50 Meet Professor Harris Basics02:16 DNA RNA Explained03:38 RNA Splicing And Ageing05:48 What Senescent Cells Do07:38 Reversing Senescence Window09:01 Fat Tissue And Faster Ageing11:01 Splicing As Central Hallmark12:11 Rejuvenation Discovery Story13:52 From Lab To Spinout Company16:41 Translating Science To Products19:17 Therapy Targets IPF And Beyond21:45 Why Translation Often Fails23:19 Defining Real Rejuvenation25:14 Avoiding Hype In Longevity27:17 Who Is Lagging Behind27:37 Regulatory Mindset Shift28:47 Trials Built for Ageing29:28 Scepticism and Overhype31:25 Is Ageing a Disease32:49 Policy and Demographic Timebomb33:48 Advocacy and Communication35:24 Personal Ageing Habits36:24 Key Unasked Questions39:15 Longevity for the Rich41:43 Access via NHS and Patents45:06 Rapid Fire and Myths49:05 Closing Reflections

Recorded at the 2026 VIVE conference in Los Angeles, this Beyond Longevity mini-series episode features Mark Zemel, co-founder and CEO of Retia Medical, discussing the company’s hemodynamic monitoring technology that turns continuous bedside physiological signals into real-time clinical insights for high-risk surgery and critical care.Marc explains Retia’s aim to detect early deterioration, guide diagnosis and therapy, and avoid the unreliability, invasiveness and complexity of older tools, noting deployment in 75 US hospitals and distribution via Medtronic, plus presence in 18 countries.He highlights FDA clearance for Argos Infinity enterprise software, which extends insights across the hospital and to clinicians’ phones and laptops, and shares a case where rapid detection of falling stroke volume revealed bleeding during AAA repair. The conversation covers workflow-first design, interoperability, cybersecurity, regulatory strategy, and a future path from ICU to broader wards and ultimately wearables for earlier intervention and preventative care.00:00 Beyond Longevity Intro00:44 Meet Mark Zeel01:40 Rata Medical Mission02:54 Argos Infinity Launch03:58 Clinicians Want Real Time05:19 Surgery Near Miss Story07:20 Why Accuracy Matters08:42 Why Algorithms Are Hard10:08 From ICU To Wearables12:20 Scaling Distribution Globally13:22 Plug And Play Integration15:22 Wearables And Data Overload18:31 Alerts And Clinical Judgment20:16 AI As Decision Support21:56 US Versus Europe Markets23:09 Wearables Beyond EMRs23:57 Regulation And Cybersecurity25:07 FDA And AI Pathways26:50 Clinician Workflow Design29:39 Bad Data From Friction31:58 Open Ecosystems Future33:25 Prevention And Longevity35:46 Personal Why Wearables Matter39:24 From ICU To Early Detection41:44 Rapid Fire And Wrap

This week’s guest is Avivah Wittenberg-Cox. Avivah advises leaders on gender and generational balance, the future of work, and the longevity economy. She hosts the podcast 4-Quarter Lives, publishes the Substack Elderberries, and writes regularly for Forbes and Harvard Business Review. She is Visiting Faculty at Oxford’s Saïd Business School, co-directs the Longevity Leadership Programme at Católica Lisbon, and has given three TED Talks.In this episode, Avivah and Daphna explore how longer lives are reshaping work, business, and society. Avivah argues that longevity is not just a health story but a structural shift that is forcing organisations to rethink how they are built, how careers unfold, and how different generations work together.She explains why the old pyramid model of the workforce is giving way to a more square demographic reality, with far more balance between younger and older generations than most institutions were designed for. That shift brings real pressure, from pensions to healthcare, but also major opportunities for businesses willing to adapt.The conversation looks at why older workers are still too often overlooked, what businesses lose when they fail to value experience, and why age-inclusive thinking is becoming a strategic advantage rather than a social add-on. More broadly, the episode challenges outdated assumptions about ageing and asks what it would mean to build a society that treats longer lives as a source of possibility, not decline.This episode is a reminder that longevity is not only changing how long we live, but how we work, lead, learn, and contribute across the course of our lives.https://www.avivahwittenbergcox.com/https://elderberries.substack.comhttps://elderberries.substack.com/podcasthttps://www.ted.com/search?q=Avivah+Wittenberg+Coxhttps://20-first.com/https://www.forbes.com/sites/avivahwittenbergcox/#61c5a38ebf1900:00 Longevity Meets Work02:06 Longevity Mega Trend03:09 Institutions Lag Behind05:37 From Gender To Age07:39 Women And Longer Lives10:08 Multi Stage Careers11:26 Rethinking Education Midlife15:29 Rebranding Old Age17:54 Opportunity And Ageism21:24 Fear Of Ageing And Happiness25:37 Goldman Sachs And AI27:17 Company First Mover Advantage28:43 Who Is Leading The Way29:52 Brands Embrace Pro Ageing30:21 Longevity In Hospitality31:12 Retirees As Consultants31:56 Why Leaders Miss Demographics35:29 Government Levers And Limits38:34 The Square Society Shift40:43 Measuring Longevity Readiness43:25 Advice Four Quarter Lives47:54 Designing A Four Quarter Life53:22 Ageing Better Than Expected54:46 Rapid Fire And Wrap Up